IN2014MN02485A - - Google Patents
Info
- Publication number
- IN2014MN02485A IN2014MN02485A IN2485MUN2014A IN2014MN02485A IN 2014MN02485 A IN2014MN02485 A IN 2014MN02485A IN 2485MUN2014 A IN2485MUN2014 A IN 2485MUN2014A IN 2014MN02485 A IN2014MN02485 A IN 2014MN02485A
- Authority
- IN
- India
- Prior art keywords
- methyl
- pentahydroxyhexyl
- dihydroquinoline
- carboxamide
- oxo
- Prior art date
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 4
- OQZQXOFJGSSYNX-UHFFFAOYSA-N 1,2-dihydroquinoline-3-carboxamide Chemical compound C1=CC=C2NCC(C(=O)N)=CC2=C1 OQZQXOFJGSSYNX-UHFFFAOYSA-N 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- -1 pentahydroxyhexyl Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 abstract 1
- 229960004577 laquinimod Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644054P | 2012-05-08 | 2012-05-08 | |
| PCT/US2013/039911 WO2013169746A2 (en) | 2012-05-08 | 2013-05-07 | N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl) amino)-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02485A true IN2014MN02485A (de) | 2015-07-17 |
Family
ID=49551433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2485MUN2014 IN2014MN02485A (de) | 2012-05-08 | 2013-05-07 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8809537B2 (de) |
| EP (1) | EP2697201A4 (de) |
| KR (1) | KR20150022816A (de) |
| CN (1) | CN104395291B (de) |
| AR (1) | AR090975A1 (de) |
| AU (1) | AU2013259779B2 (de) |
| BR (1) | BR112014028121A2 (de) |
| CA (1) | CA2873258A1 (de) |
| EA (1) | EA201492029A1 (de) |
| HK (1) | HK1207080A1 (de) |
| IL (1) | IL235338A0 (de) |
| IN (1) | IN2014MN02485A (de) |
| MX (1) | MX2014013664A (de) |
| NZ (1) | NZ630549A (de) |
| SG (1) | SG11201407447XA (de) |
| TW (1) | TW201350467A (de) |
| UY (1) | UY34791A (de) |
| WO (1) | WO2013169746A2 (de) |
| ZA (1) | ZA201408825B (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR089862A1 (es) | 2012-02-03 | 2014-09-24 | Teva Pharma | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA |
| MX2014009889A (es) | 2012-02-16 | 2014-11-13 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos. |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| MX2015005632A (es) | 2012-11-07 | 2016-02-05 | Teva Pharma | Sales de amina de laquinimod. |
| EP2970129A2 (de) | 2013-03-14 | 2016-01-20 | Teva Pharmaceutical Industries Ltd. | Kristalle aus laquinimodnatrium und verbessertes verfahren zur herstellung davon |
| KR20170005434A (ko) | 2014-04-29 | 2017-01-13 | 테바 파마슈티컬 인더스트리즈 리미티드 | 높은 장애 상태를 갖는 재발-완화형 다발성 경화증(rrms) 환자 치료용 라퀴니모드 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2159804A (en) * | 1937-11-23 | 1939-05-23 | Du Pont | N-nitroaryl polyhydroxy alkyl amino compounds and process of preparing the same |
| IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| US4782155A (en) | 1986-03-19 | 1988-11-01 | Banyu Pharmaceutical Co., Ltd. | Cephalosporin derivatives, processes for their preparation and antibacterial agents |
| SE8902076D0 (sv) | 1989-06-09 | 1989-06-09 | Pharmacia Ab | Derivatives of quinoline-3-carboxanilide |
| US5139878A (en) | 1991-08-12 | 1992-08-18 | Allied-Signal Inc. | Multilayer film constructions |
| US6043006A (en) * | 1997-09-04 | 2000-03-28 | Fuji Photo Film Co., Ltd. | 4-(N,N-dialkylamino)aniline compound, photographic processing composition containing the same and color image-forming method |
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6133285A (en) | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
| US6121287A (en) | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
| SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| JP4980527B2 (ja) | 1999-06-07 | 2012-07-18 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 酸に不安定な活性化合物を含有する新規の製剤および投与形 |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US7560557B2 (en) | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
| US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| SG10201508623RA (en) | 2005-10-19 | 2015-11-27 | Teva Pharma | Crystals of laquinimod sodium, and process for the manufacture thereof |
| KR20150065951A (ko) | 2006-06-12 | 2015-06-15 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
| KR20100105802A (ko) | 2007-04-19 | 2010-09-29 | 콘서트 파마슈티컬즈, 인크. | 중수소화된 모르폴리닐 화합물 |
| WO2009082471A1 (en) | 2007-12-20 | 2009-07-02 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| MX2011002033A (es) | 2008-09-03 | 2011-05-02 | Teva Pharma | 2-oxo-1,2-dihidro-quinolinas moduladoras de la funcion inmune. |
| US20120009226A1 (en) * | 2008-12-17 | 2012-01-12 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
| EP2228367A1 (de) * | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Zusatzsalze von Aminen mit Hydroxyl- und/oder Carboxylgruppen mit Aminonicotinsäurederivaten als DHODH-Inhibitoren |
| EP2442651B1 (de) | 2009-06-19 | 2015-07-29 | Teva Pharmaceutical Industries Ltd. | Behandlung multipler sklerose mit laquinimod |
| ES2564931T3 (es) | 2009-07-30 | 2016-03-30 | Teva Pharmaceutical Industries Ltd. | Tratamiento de enfermedad de Crohn con laquinimod |
| CA2771203C (en) | 2009-08-10 | 2019-04-09 | Teva Pharmaceutical Industries Ltd. | Treatment of bdnf-related disorders using laquinimod |
| MX2012010066A (es) | 2010-03-03 | 2012-10-03 | Teva Pharma | Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato. |
| WO2011109526A1 (en) | 2010-03-03 | 2011-09-09 | Teva Pharmaceutical Industries Ltd. | Treatment of lupus nephritis using laquinimod |
| US20110217295A1 (en) | 2010-03-03 | 2011-09-08 | Asi Haviv | Treatment of lupus arthritis using laquinimod |
| CN104610144A (zh) | 2010-07-09 | 2015-05-13 | 泰华制药工业有限公司 | 氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途 |
| EA201390074A1 (ru) | 2010-07-09 | 2013-06-28 | Тева Фармасьютикал Индастриз Лтд. | 5-хлор-4-гидрокси-1-метил-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид, его соли и применения |
| JP2012047974A (ja) * | 2010-08-26 | 2012-03-08 | Toshiba Corp | 映像表示装置及び映像表示方法 |
| KR20130065728A (ko) * | 2010-10-14 | 2013-06-19 | 임뮤나르 에이비 | Ahr 활성화제로서의 1,2-디히드로-4-히드록시-2-옥소-퀴놀린-3-카르복사닐리드 |
| CA2820586A1 (en) | 2010-12-07 | 2012-06-14 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
| CN103781354A (zh) | 2011-07-28 | 2014-05-07 | 泰华制药工业有限公司 | 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症 |
| SG10201606204TA (en) | 2011-07-28 | 2016-09-29 | Teva Pharma | Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Interferon-Beta |
| EP2766020A4 (de) | 2011-10-12 | 2015-04-01 | Teva Pharma | Behandlung von multipler sklerose mit einer kombination aus laquinimod und fingolimod |
-
2013
- 2013-05-02 TW TW102115767A patent/TW201350467A/zh unknown
- 2013-05-07 AR ARP130101569A patent/AR090975A1/es unknown
- 2013-05-07 CN CN201380029448.XA patent/CN104395291B/zh not_active Expired - Fee Related
- 2013-05-07 CA CA2873258A patent/CA2873258A1/en not_active Abandoned
- 2013-05-07 US US13/888,709 patent/US8809537B2/en not_active Expired - Fee Related
- 2013-05-07 EP EP13750833.9A patent/EP2697201A4/de not_active Withdrawn
- 2013-05-07 BR BR112014028121A patent/BR112014028121A2/pt not_active IP Right Cessation
- 2013-05-07 AU AU2013259779A patent/AU2013259779B2/en not_active Expired - Fee Related
- 2013-05-07 HK HK15107804.4A patent/HK1207080A1/xx unknown
- 2013-05-07 UY UY0001034791A patent/UY34791A/es not_active Application Discontinuation
- 2013-05-07 WO PCT/US2013/039911 patent/WO2013169746A2/en not_active Ceased
- 2013-05-07 IN IN2485MUN2014 patent/IN2014MN02485A/en unknown
- 2013-05-07 MX MX2014013664A patent/MX2014013664A/es unknown
- 2013-05-07 NZ NZ630549A patent/NZ630549A/en not_active IP Right Cessation
- 2013-05-07 SG SG11201407447XA patent/SG11201407447XA/en unknown
- 2013-05-07 KR KR20147034461A patent/KR20150022816A/ko not_active Withdrawn
- 2013-05-07 EA EA201492029A patent/EA201492029A1/ru unknown
-
2014
- 2014-10-26 IL IL235338A patent/IL235338A0/en unknown
- 2014-12-02 ZA ZA2014/08825A patent/ZA201408825B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013259779B2 (en) | 2017-06-08 |
| TW201350467A (zh) | 2013-12-16 |
| US8809537B2 (en) | 2014-08-19 |
| EP2697201A4 (de) | 2014-11-26 |
| KR20150022816A (ko) | 2015-03-04 |
| AU2013259779A1 (en) | 2014-12-18 |
| CN104395291B (zh) | 2017-07-28 |
| AR090975A1 (es) | 2014-12-17 |
| WO2013169746A2 (en) | 2013-11-14 |
| IL235338A0 (en) | 2014-12-31 |
| ZA201408825B (en) | 2016-07-27 |
| CN104395291A (zh) | 2015-03-04 |
| HK1207080A1 (en) | 2016-01-22 |
| CA2873258A1 (en) | 2013-11-14 |
| WO2013169746A3 (en) | 2013-12-05 |
| EA201492029A1 (ru) | 2015-06-30 |
| MX2014013664A (es) | 2015-04-17 |
| US20130345256A1 (en) | 2013-12-26 |
| NZ630549A (en) | 2016-01-29 |
| UY34791A (es) | 2013-11-29 |
| SG11201407447XA (en) | 2015-02-27 |
| EP2697201A2 (de) | 2014-02-19 |
| BR112014028121A2 (pt) | 2017-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN10670A (de) | ||
| PH12018501956A1 (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| PH12015500064B1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| EA033689B9 (ru) | Ингибиторы g12c kras | |
| PH12016501310B1 (en) | Pharmaceutical compositions comprising azd9291 | |
| MX2015011984A (es) | Inhibidores de bromodominio de dihidro-pirrolopiridinona. | |
| PL402710A1 (pl) | Kompozycje farmaceutyczne zawierajace imatinib lub jego farmaceutycznie dopuszczalna sól oraz sposoby ich otrzymywania | |
| MX2016007440A (es) | Inhibidores del bromodominio. | |
| AU2018297348A1 (en) | Compositions for parenteral administration of therapeutic agents | |
| MX2014013664A (es) | N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-n-fenil-1,2-dihidroquinolin-3-carboxamida. | |
| PH12016502246B1 (en) | Carboxamide derivatives | |
| MX2016013431A (es) | Composiciones farmaceuticas que comprenden agentes antibacterianos. | |
| EP3103453A4 (de) | Medizinische zusammensetzung mit heterocyclischer diamino-carboxamid-verbindung als wirkstoff | |
| EP3493808A4 (de) | Pharmazeutische zusammensetzungen von ibrutinib | |
| HK1198296A1 (en) | N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof | |
| MX2013008269A (es) | Composicion farmaceutica que comprende derivados de piridona. | |
| WO2019004980A3 (en) | SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN DEXILATE | |
| IN2013MU03421A (de) | ||
| MX2016005539A (es) | Composiciones farmaceuticas que comprenden agentes antibacterianos. | |
| MX2016013428A (es) | Composiciones farmaceuticas que comprenden agentes antibacterianos. | |
| IN2013MU03309A (de) | ||
| MX2018010652A (es) | Composiciones farmaceuticas. | |
| IN2014MU01194A (de) | ||
| HK40052632A (en) | Methods and compositions for delivery of agents across the blood-brain barrier | |
| GB2569616B (en) | Sustained release oral pharmaceutical compositions of dicycloverine |